Curium
Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.
Private radiopharma group (SPECT and PET isotopes, generators). ECLIPSE phase 3 of 177Lu-PSMA-I&T met its rPFS endpoint in taxane-naive mCRPC; Japanese registrational trial with PeptiDream/PDRadiopharma enrolled its first patient February 2026. Regulatory submission plan under discussion with FDA.
177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
Pages like this
not linked directly; found by shared links- CompanyEckert & Ziegler
Shares Radionuclide generators and cold kits, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Radiopharmacy and cyclotron networks.
- CompanyLantheus
Shares 177Lu-PSMA-I&T, Radionuclide generators and cold kits, Prostate cancer.
- TrialECLIPSE
Shares 177Lu-PSMA-I&T, Prostate cancer.
- TrialSPLASH
Shares 177Lu-PSMA-I&T, Prostate cancer.
- PersonPeter Bartenstein
Shares 177Lu-PSMA-I&T, Prostate cancer.
- CompanyTerraPower Isotopes
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Manufacturing cost and time for living and radioactive medicines.
- CompanyITM Isotope Technologies Munich
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Manufacturing cost and time for living and radioactive medicines.
- TechnologyMedical cyclotrons, hot cells, and synthesis modules
Shares Radionuclide generators and cold kits, Radiopharmacy and cyclotron networks.